Alexander W. Schüttelkopf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexander W. Schüttelkopf has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Christopher H. Gray
Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
27 shared publicationsDuncan McArthur
Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
27 shared publicationsJennifer Konczal
Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
27 shared publicationsJustin Bower
Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
27 shared publicationsMokdad Mezna
Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
27 shared publicationsAbdulrahman Hussain Qaisi
26 shared publications
Latest Publications
- 31 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9129-9161
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A subseries of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent multivariant Ras inhibitors can be accessed from this novel pocket.
- 31 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9129-9161
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A subseries of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent multivariant Ras inhibitors can be accessed from this novel pocket.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Summary of the properties of BDP-9066
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Summary of the properties of BDP-9066
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary video 5 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Subconfluent migration assays in the presence of 1000nM BDP-9066
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary video 5 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Subconfluent migration assays in the presence of 1000nM BDP-9066
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary video figure legend from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Supplementary video figure legend
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary video figure legend from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Supplementary video figure legend
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Antibodies used for western blotting
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Antibodies used for western blotting
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary video 6 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Ex vivo migration assay in the presence of BDP-9066.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary video 6 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Ex vivo migration assay in the presence of BDP-9066.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary video 3 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Subconfluent migration assay in the presence of DMSO
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary video 3 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Subconfluent migration assay in the presence of DMSO
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Confirmation of tumour volume (MRI), levels of circulating BDP-9066 and CT guided RT
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Confirmation of tumour volume (MRI), levels of circulating BDP-9066 and CT guided RT
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary video 4 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Subconfluent migration assays in the presence of 100nM BDP-9066
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary video 4 from A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma
Subconfluent migration assays in the presence of 100nM BDP-9066